273 related articles for article (PubMed ID: 33988236)
1. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
[TBL] [Abstract][Full Text] [Related]
2. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
[TBL] [Abstract][Full Text] [Related]
3. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Khoury A; Pagan KA; Farland MZ
Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
[TBL] [Abstract][Full Text] [Related]
4. Oral Ferric Maltol for the Treatment of Iron-Deficiency Anemia in Patients With CKD: A Randomized Trial and Open-Label Extension.
Pergola PE; Kopyt NP
Am J Kidney Dis; 2021 Dec; 78(6):846-856.e1. PubMed ID: 34029682
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
6. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
Schmidt C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Howaldt S; Stallmach A; Büning C;
Aliment Pharmacol Ther; 2016 Aug; 44(3):259-70. PubMed ID: 27237709
[TBL] [Abstract][Full Text] [Related]
7. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
Gasche C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Büning C; Howaldt S; Stallmach A;
Inflamm Bowel Dis; 2015 Mar; 21(3):579-88. PubMed ID: 25545376
[TBL] [Abstract][Full Text] [Related]
8. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S
Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
[TBL] [Abstract][Full Text] [Related]
9. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia.
Lyseng-Williamson KA; Keating GM
Drugs; 2009; 69(6):739-56. PubMed ID: 19405553
[TBL] [Abstract][Full Text] [Related]
10. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.
Qunibi WY; Martinez C; Smith M; Benjamin J; Mangione A; Roger SD
Nephrol Dial Transplant; 2011 May; 26(5):1599-607. PubMed ID: 20929915
[TBL] [Abstract][Full Text] [Related]
12. Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response Among Patients With Acute Isovolemic Anemia Following Gastrectomy: The FAIRY Randomized Clinical Trial.
Kim YW; Bae JM; Park YK; Yang HK; Yu W; Yook JH; Noh SH; Han M; Ryu KW; Sohn TS; Lee HJ; Kwon OK; Ryu SY; Lee JH; Kim S; Yoon HM; Eom BW; Choi MG; Kim BS; Jeong O; Suh YS; Yoo MW; Lee IS; Jung MR; An JY; Kim HI; Kim Y; Yang H; Nam BH;
JAMA; 2017 May; 317(20):2097-2104. PubMed ID: 28535237
[TBL] [Abstract][Full Text] [Related]
13. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
14. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP).
Breymann C; Milman N; Mezzacasa A; Bernard R; Dudenhausen J;
J Perinat Med; 2017 May; 45(4):443-453. PubMed ID: 27278921
[TBL] [Abstract][Full Text] [Related]
15. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
[TBL] [Abstract][Full Text] [Related]
16. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
Toblli JE; Di Gennaro F
PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
[TBL] [Abstract][Full Text] [Related]
17. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
Bokemeyer B; Krummenerl A; Maaser C; Howaldt S; Mroß M; Mallard N
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):229-238. PubMed ID: 27101422
[TBL] [Abstract][Full Text] [Related]
18. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
Sobrado CW; Cançado RD; Sobrado LF; Frugis MO; Sobrado MF
Arq Gastroenterol; 2015 Dec; 52(4):255-9. PubMed ID: 26840464
[TBL] [Abstract][Full Text] [Related]
19. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
